v3.21.1
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury stock
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2019 $ (8,172) $ 18 $ (24,504) $ 15,193 $ 4,717 $ (3,596) $ 0
Beginning balance (in shares) at Dec. 31, 2019   1,479          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 3,010 $ 0 0 0 3,010 0 0
Other comprehensive income (loss), net of tax (101) 0 0 0 0 (101) 0
Dividends declared (1,754) 0 0 0 (1,754) 0 0
Purchases of treasury stock (643) $ 0 (643) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 245 $ 0 37 208 0 0 0
Stock-based compensation plans and other (in shares)   5          
Ending balance at Mar. 31, 2020 (7,415) $ 18 (25,110) 15,401 5,973 (3,697) 0
Ending balance (in shares) at Mar. 31, 2020   1,477          
Beginning balance at Dec. 31, 2020 13,097 $ 18 (2,264) 17,384 1,055 (3,117) 21
Beginning balance (in shares) at Dec. 31, 2020   1,765          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 3,553 $ 0 0 0 3,553 0 0
Other comprehensive income (loss), net of tax (178) 0 0 0 0 (178) 0
Dividends declared (2,316) 0 0 0 (2,316) 0 0
Purchases of treasury stock (787) $ 0 (787) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 362 $ 0 34 328 0 0 0
Stock-based compensation plans and other (in shares)   8          
Change in noncontrolling interest 2 $ 0 0 0 0 0 2
Ending balance at Mar. 31, 2021 $ 13,733 $ 18 $ (3,017) $ 17,712 $ 2,292 $ (3,295) $ 23
Ending balance (in shares) at Mar. 31, 2021   1,766